The short version
Just 3 companies supply this market — thin enough that a single exit would be felt immediately. The price is down 25% over the past year, to $938.69 per mL.
Market view
adalimumab-bwwd · Solution
11 marketed package NDCs · 3 active manufacturers
Most dispensed: ADALIMUMAB 40 mg/.4mL · Solution · #2 syringes/carton / .4 ml in 1 syringe · ADALIMUMAB 40 mg/.8mL · Solution · #2 cartons/carton / 1 syringe in 1 carton / .8 ml in 1 syringe
Price range and competition
RSS: changes for this drugEvery company selling this drug reports its own price. The line follows the middle of the pack; the shaded band holds the middle half of companies — the wider it is, the more they disagree.
Latest · Sep 2026 — typical price $938.69 · middle half $621.05–$1255.67 · full range $615.91–$1258.83 · 4 products · 3 companies
ⓘ How this was built
Data sources
- CMS NADAC weekly survey + monthly archives back to 2013 (data.medicaid.gov)
- CMS Federal Upper Limit files (weighted AMP)
- FDA NDC Directory (openFDA) — maker roster
Method
Each month's band spans the NADAC unit prices of every NDC of this drug (min, quartiles, median, max), split into brand and generic cohorts by FDA marketing category. Maker counts come from distinct labelers with the NDC actively listed.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
What changed in the last 90 days
Every detected change for adalimumab-bwwd, newest first — price moves, shortages, recalls, and manufacturers entering or leaving. Detected by comparing each day’s federal data against the day before.
- HadlimaAug 19, 2026Price downNADAC $1260.33059 → $1258.83396 per unit (-0.12%)
- HadlimaAug 19, 2026Price downNADAC $1254.77717 → $1254.61304 per unit (-0.01%)
- HadlimaAug 19, 2026Price upNADAC $611.955 → $615.91146 per unit (+0.65%)
- HadlimaJul 22, 2026Price downNADAC $634.475 → $622.75859 per unit (-1.85%)
- HadlimaJul 22, 2026Price upNADAC $1259.34333 → $1260.33059 per unit (+0.08%)
- HadlimaJul 22, 2026Price downNADAC $1257.07153 → $1254.77717 per unit (-0.18%)
- HadlimaJul 22, 2026Price upNADAC $611.35125 → $611.955 per unit (+0.1%)
Same drug class
Other molecules FDA puts in Tumor Necrosis Factor Blocker, with whether each is in shortage right now. Same class is not the same drug — substitution is a clinical decision, and this is a supply picture, not a recommendation.
Common questions
- Is Adalimumab-bwwd in shortage right now?
- No. FDA does not currently list Adalimumab-bwwd in shortage. This page is rebuilt every morning from FDA's shortage database, so a new posting appears here the day it is published.
- Who makes Adalimumab-bwwd?
- 3 companies have marketed Adalimumab-bwwd in the last 30 days, according to the FDA NDC Directory. That is a thin market — if one stops making it, supply is at risk quickly. Every manufacturer and package is listed on this page.
- What does Adalimumab-bwwd cost?
- The typical pharmacy pays about $938.69 per mL, based on the most recent CMS NADAC survey of actual acquisition costs. That is what the pharmacy pays for the drug itself — not the cash price, and not what an insurer is billed.
All marketed products
Expand a strength to see its dosage forms, then package sizes, then each manufacturer and NDC. Click an NDC for its full detail page.